Assessment of Bone Mineral Density Decline in Prostate Cancer Patients Undergoing Hormonal Therapy
DOI:
https://doi.org/10.56294/hl2025638Keywords:
Prostate cancer, medical care, hormonal therapy, bone wellness, risk factorsAbstract
Introduction: The prostate cancer is a highly prevalent cancer in men, and enhanced screening and treatment have helped in earlier detection and greater longevity. However, due to complications, patients' quality of life has grown more crucial. Despite regional therapy, Prostate cancer naturally develops to metastasis, notably in the bone, increasing mortality and morbidity from skeletal-related events and necessitating operation or therapy. The objective of the article is to analyze the influence of various hormone therapies on bone mineral density, termed Bone Mineral Density(BMD) in individuals with prostate cancer.
Methods: The research includes two groups, in Group A patients who have prostate cancer take the treatment named Luteinizing Hormone-Releasing Hormone agonists (LHRH), and for Group B patients, the treatment called anti-androgen hormonal therapy. It particularly analyses the impact of LHRH in Group A on anti-androgen medication in Group B.
Results: A questionnaire was presented to the patients to gather data on several parameters such as medical information, and lifestyle behaviors. A paired t-test and multiple linear regression analyses were carried out using the SPSS software version 28, to investigate the impact of hormonal treatment on BMD results.
Conclusion: The research found that age, duration of hormone therapy, BMI, and baseline BMD were significant indicators of BMD changes among patients with prostate cancer. The results suggest that group A, which was undergoing LHRH treatment, is more successful in maintaining BMD, compared to the group B, which emerged from anti-androgen therapy.
References
1. Papadopoulos E, Santa Mina D, Culos-Reed N, Durbano S, Ritvo P, Sabiston CM, Krahn M, Tomlinson G, O'Neill M, Iqbal A, Timilshina N. Effects of six months of aerobic and resistance training on metabolic markers and bone mineral density in older men on androgen deprivation therapy for prostate cancer. Journal of geriatric oncology. 2020 Sep 1;11(7):1074-7. 10.1002/med.21778
2. Miyake M, Tatsumi Y, Ohnishi K, Fujii T, Nakai Y, Tanaka N, Fujimoto K. Prostate diseases and microbiome in the prostate, gut, and urine. Prostate international. 2022 Jun 1;10(2):96-107. https://doi.org/10.1016/j.prnil.2022.03.004
3. Dalla Volta A, Mazziotti G, Maffezzoni F, Grisanti S, Palumbo C, Pedersini R, Maroldi R, Berruti A. Bone mineral density and FRAX score may not predict fracture risk in patients with cancer undergoing hormone deprivation therapies. Journal of Clinical Oncology. 2020 Oct 10;38(29):3363-6. https://dx.doi.org/10.18203/2320-6012.ijrms20222617
4. Takahashi S. Management of cancer treatment-induced bone loss (CTIBL) in patients with breast cancer or prostate cancer. Journal of Bone and Mineral Metabolism. 2023 May;41(3):307-16.https://doi.org/10.1007/s00774-023-01414-1
5. Brown JE, Handforth C, Compston JE, Cross W, Parr N, Selby P, Wood S, Drudge-Coates L, Walsh JS, Mitchell C, Collinson FJ. Guidance for the assessment and management of prostate cancer treatment-induced bone loss. A consensus position statement from an expert group. Journal of Bone Oncology. 2020 Dec 1;25:100311. 9.https://doi.org/10.1016/j.jbo.2020.100311
6. Sølling AS, Harsløf T, Brockstedt HK, Langdahl B. Discontinuation of denosumab in men with prostate cancer. Osteoporosis International. 2023 Feb;34(2):291-7.https://doi.org/10.1007/s00198-022-06610-9
7. Baldessari C, Pipitone S, Molinaro E, Cerma K, Fanelli M, Nasso C, Oltrecolli M, Pirola M, D’Agostino E, Pugliese G, Cerri S. Bone metastases and health in prostate cancer: From pathophysiology to clinical implications. Cancers. 2023 Feb 28;15(5):1518.https://doi.org/10.3390/cancers15051518
8. Bowling GC, Albright JA, Maloney TJ, Quinn MS, Daniels AH, Chesnut GT. Poor Bone Mineral Density Is Associated With Increased Risk of Urological Bone Metastases. Urology. 2024 Oct 1;192:88-96.https://doi.org/10.1016/j.urology.2024.04.043
9. Ali A, Hoyle A, Haran ÁM, Brawley CD, Cook A, Amos C, Calvert J, Douis H, Mason MD, Dearnaley D, Attard G. Association of bone metastatic burden with survival benefit from prostate radiotherapy in patients with newly diagnosed metastatic prostate cancer: a secondary analysis of a randomized clinical trial. JAMA oncology. 2021 Apr 1;7(4):555-63.10.1001/jamaoncol.2020.7857
10. Hara T, Nishimoto H, Terakawa T, Okamura Y, Suzuki K, Bando Y, Chiba K, Hyodo Y, Teishima J, Nakano Y, Kuroda R. Temporal declines in bone mineral density and trabecular bone score during androgen deprivation therapy. Journal of Bone and Mineral Metabolism. 2024 Nov;42(6):668-74.https://doi.org/10.1007/s00774-024-01537-z
11. Khriguian J, Tsui JM, Vaughan R, Kucharczyk MJ, Nabid A, Bettahar R, Vincent L, Martin AG, Jolicoeur M, Yassa M, Barkati M. The clinical significance of bone mineral density changes following Long-Term androgen deprivation therapy in localized prostate cancer patients. Urology. 2021 Jun;205(6):1648-54.https://doi.org/10.1097/JU.0000000000001646
12. Hussain A, Tripathi A, Pieczonka C, Cope D, McNatty A, Logothetis C, Guise T. Bone health effects of androgen-deprivation therapy and androgen receptor inhibitors in patients with nonmetastatic castration-resistant prostate cancer. Prostate cancer and prostatic diseases. 2021 Jun;24(2):290-300.https://doi.org/10.1038/s41391-020-00296-y
13. Mazziotti G, Vena W, Pedersini R, Piccini S, Morenghi E, Cosentini D, Zucali P, Torrisi R, Sporeni S, Simoncini EL, Maroldi R. Prediction of vertebral fractures in cancer patients undergoing hormone deprivation therapies: reliability of who fracture risk assessment tool (frax) and bone mineral density in real-life clinical practice. Journal of Bone Oncology. 2022 Apr 1;33:100421.https://doi.org/10.1016/j.jbo.2022.100421
14. Suarez-Almazor ME, Pundole X, Cabanillas G, Lei X, Zhao H, Elting LS, Lopez-Olivo MA, Giordano SH. Association of bone mineral density testing with risk of major osteoporotic fractures among older men receiving androgen deprivation therapy to treat localized or regional prostate cancer. JAMA network open. 2022 Apr 1;5(4):e225432-.doi:10.1001/jamanetworkopen.2022.5432
15. Khan MI. Management of bone loss due to endocrine therapy during cancer treatment. Osteoporosis International. 2023 Apr;34(4):671-80.https://doi.org/10.1007/s00198-023-06672-3
16. Ojewuyi OO, Ikuerowo SO, Jeje EA, Adewole OA, Abolarinwa AA, Omisanjo OA. Bone mineral density in Nigerian men on androgen deprivation therapy for advanced prostate cancer. African Journal of Urology. 2020 Dec;26:1-6.https://doi.org/10.1186/s12301-020-00036-7.
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Rakesh Sankaran, Ganapathy G. Bhavani, Jyoti Prakash Samal, Nitish Vashisht , Kothakonda Sairam, Lakshay Bareja (Author)
This work is licensed under a Creative Commons Attribution 4.0 International License.
The article is distributed under the Creative Commons Attribution 4.0 License. Unless otherwise stated, associated published material is distributed under the same licence.
